2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5936 Four-year follow-up from a phase 1/2 trial of LV20.19 CAR T cells for relapsed, refractory mantle cell lymphoma

Gulrayz Ahmed, MD, Farah Yassine, MD, MSc2, Kaitlin Annunzio, MD3, Aniko Szabo, PhD4, Tyce Kearl, MD, PhD5, Bryon Johnson, PhD6, Peiman Hematti, MD7, Walter Longo, MD8, Timothy Fenske, MD9, Mehdi Hamadani, MD10, Nirav N. Shah, MD, MS11
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Introduction:

Mantle cell lymphoma (MCL) is a rare form of B cell non-Hodgkin lymphoma (NHL) characterized by t(11;14) and bright CD20 expression with a relapsing/remitting course in most patients (pts). Novel therapeutics, including CD19 chimeric antigen receptor (CAR) T cell therapies, have offered new options for pts with relapsed, refractory (R/R) MCL. However, the two currently FDA-approved CD19 CAR T cell products remain limited by early toxicity (Grade 3 ICANS in ~30%) with brexu-cel, and modest progression-free survival (PFS) of 15.3 months with liso-cel. We previously reported initial outcomes of dual targeting lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T cells using an adaptive manufacturing process, part of a phase 1/2 clinical trial in R/R MCL, as an approach to improve outcomes in R/R MCL. In our initial publication, we reported an overall response rate (ORR) of 100% and median PFS that was not reached with 16 months of follow-up (Shah NN. et al. JCO 2025) and no Grade 3+ CRS. Here we report the outcomes of a long-term follow-up of our study population.

 

Methods:

This is a phase 1/2 single center trial (NCT04186520) evaluating LV20.19 CAR T cells at a fixed dose of 2.5e6 cells/kg for pts with R/R B cell NHL including a dedicated cohort in MCL. The LV20.19 CAR T cell product was manufactured on site using CliniMACS Prodigy and rapid manufacturing timeline of 8-12 days with a goal of fresh infusion. Patients who survived beyond 2 years were consented to a long-term follow-up protocol (NCT03375619) for further monitoring of late toxicities, relapse, and death for up to 15 years post LV20.19 CAR T cells. Key outcomes were to evaluate pts for persistence of CAR T cells, relapses of primary malignancy, development of second primary malignancies, and immune reconstitution. Descriptive statistics were utilized for demographic data and the Kaplan Meier methodology for survival analysis.

 

Results:

Seventeen pts with R/R MCL received LV20.19 CAR T cells (Phase 1=3 pts and Phase 2=14 pts). The median age was 63 (50-74 years) and 15 pts (88%) were male. The median number of prior therapies was 4 (3-8). The day 28 ORR was 100%, complete remission (CR) rate 76% and partial response (PR) rate 24%. There were two early non-relapse mortalities within the first-year post CAR T due to gram negative sepsis and COVID19 infection.

We now report updated results with a median follow-up of 47.6 months (range 38.4 – 72.7) for surviving pts. The 4-year PFS was 53% and 4-year overall survival (OS) was 71%. Median OS was not reached to date. In total, only 4 pts (24%) experienced relapsed MCL. Six pts (35%) developed second primary malignancies. Among these, three pts developed a new hematological malignancy including a new diagnosis of multiple myeloma (n=1), therapy-related myelodysplastic syndrome (n=1) in a patient with prior auto-HCT and hyperCVAD chemotherapy, and a new diagnosis of peripheral T cell lymphoma (n=1). Polymerase chain reaction studies demonstrated that the new T cell malignancy was independent from the CAR-positive T cell population. Sixteen of the 17 CAR-treated pts (94%) had detectable circulating CAR T cells at the latest assessment times with a range of 0.1% - 56.0% CAR+ CD3 T cells (median of 0.39%), indicating the relative long-term persistence of CAR T cells in this patient cohort. With the long-term persistence of CAR T cells, 13 pts (76%) experienced prolonged B cell aplasia defined as an absolute B cell count <20/µL. Five pts (29%) had prolonged CD4 T cell count <200/µL. The majority of pts (n=15; 88%) received IVIG replacement.

Conclusions:

Bispecific LV20.19 CAR T cells demonstrate durable efficacy and survival for R/R MCL pts with a 4-year PFS of 53% and 4-year OS of 71%. Only 4 of 17 pts (24%) experienced relapsed MCL to date, demonstrating the ability to achieve long-term remissions with dual targeted LV20.19 CAR-T cells. Second primary malignancies occurred in about a third of pts. Patients were typically immunocompromised with prolonged B cell aplasia often requiring IVIG replacement. Earlier application of LV20.19 CAR T cell therapy may help mitigate some of the long-term toxicities. Frontline application of MB20.19 (identical construct as LV20.19) CAR T cells in high-risk MCL is under development (BMT CTN 2501), and a multi-center phase II study of MB20.19 CAR T cells in R/R MCL is actively enrolling pts (NCT04792489).

Gulrayz Ahmed, MD: No relevant conflicts of interest to declare.